POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19

Published December 1, 2022


Yahoo!Finance covered UB research co-authored by Jonathan Lovell, SUNY Empire Innovation Professor of biomedical engineering, suggesting a new COVID-19 vaccine candidate is amendable to multiple boosting regimes in the future.

"The unique qualities of the SNAP adjuvant system enabled simple conversion of protein antigens into immunogenic particles that safely induced virus-neutralizing antibodies. We look forward to further study of this technology for the prevention of COVID-19 and other diseases," said Lovell.

Read the story here.